Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.
Alexi L VasbinderElizabeth AndersonHusam ShadidHanna BerlinMichael PanTariq U AzamIbrahim KhaleelKishan PadaliaChelsea MelochePatrick O'HayerErinleigh MichaudTonimarie CatalanRafey FerozePennelope BlakelyChristopher LauniusYiyuan HuangLili ZhaoLynn AngMonica MikhaelKara Mizokami-StoutSubramaniam PennathurMatthias KretzlerSven H LoosenAthanasios ChalkiasFrank TackeEvangelos J Giamarellos-BourboulisJochen ReiserJesper Eugen-OlsenEva L FeldmanPradipta R RaySalim S Hayeknull nullSalim S HayekPennelope BlakelyHanna BerlinTariq U AzamHusam ShadidMichael PanPatrick O'HayerChelsea MelocheRafey FerozeKishan J PadaliaElizabeth AndersonDanny PerryAbbas BitarRayan KaakatiYiyuan HuangLili ZhaoJochen ReiserBeata SamelkoAlex HlepasPriya P PatelXuexiang WangJesper Eugen-OlsenIzzet AltintasMarius StauningMorten Baltzer HoulindMette B LindstrømHejdi Gamst-JensenLine Jee HartmannJan O NehlinThomas KallemoseImran ParvaizChristian RasmussenOve AndersenJens TingleffEvangelos J Giamarellos-BourboulisMaria-Evangelia AdamiNicky SolomonidiMaria TsilikaMaria SaridakiVasileios LekakisSven H LoosenTom LueddeVerena KeitelAthanasios ChalkiasEleni ArnaoutoglouIoannis PantazopoulosEleni LaouKonstantina KoloniaAnargyros SkoulakisFrank TackePinkus Tober-LauRaphael MohrFlorian KurthLeif Erik SanderChristoph JochumPublished in: Diabetes care (2022)
Our findings suggest that the association between DM and outcomes in COVID-19 is largely mediated by hyperinflammation as assessed by suPAR levels, while the impact of hyperglycemia is independent of inflammation.